Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 10, 2026Neuro-Oncology AdvancesOpen Access

Clinical and radiographic prognostic factors in recurrent contrast-enhancing IDH-Mutant Gliomas treated with Bevacizumab

View Full Paper
Ask AI
Bookmark
Share

Authors

CLCollin LeUniversity of California, Los AngelesFSFrancesco Davide SanvitoUniversity of California, Los AngelesCYCaijun YangChina XD Group (China)

Discussion

Loading...

Member takes

Overview

This retrospective analysis finds key predictors of survival in IDH-mutant gliomas treated with bevacizumab, suggesting early monitoring is beneficial.

Key Points

  • To evaluate prognostic factors influencing outcomes in IDH-mutant gliomas treated with bevacizumab.
  • Retrospective analysis of 97 patients
  • Assessment of clinical variables such as age, sex, KPS, and treatment history
  • Use of MRI data to measure tumor volume and radiographic response
  • Cox survival analyses to evaluate predictors for progression-free and overall survival
  • Median progression-free survival was 3.62 months, and overall survival was 10.49 months
  • Independent predictors of better outcomes included fewer prior recurrences, 1p19q codeletion, higher KPS, and successful radiographic response
  • Bevacizumab led to a significant reduction in corticosteroid dosage after 2 months (49% reduction).

Cite This Study

Le et al. (2026) studied this question.

synapsesocial.com/papers/69d896046c1944d70ce0729ehttps://doi.org/10.1093/noajnl/vdag089
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival2008 · 246 citations
  2. 2EP08.02 THE CLINICAL OUTCOME OF BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMAS: A POLISH SINGLE CENTER EXPERIENCE2025
  3. 3Predictive role of MGMT and IDH status in the efficacy of bevacizumab for high-grade glioma: a retrospective study2025
  4. 4Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study2026
  5. 5A prognostic model for overall survival in recurrent glioma patients treated with bevacizumab-containing therapy2024